NEW YORK - TG Therapeutics, Inc. (NASDAQ:TGTX) announced the issuance of three new patents by the United States Patent and Trademark Office (USPTO) for its drug BRIUMVI® (ublituximab-xiiy), a treatment for relapsing forms of multiple sclerosis (RMS).
The patents, which extend protection until 2042, cover the composition and treatment methods of the drug, leveraging its unique glycoprofile.
BRIUMVI® is the only anti-CD20 monoclonal antibody approved in the U.S. for RMS that can be administered in a one-hour infusion after the initial dose. This treatment is currently available for RMS patients in the U.S., including those with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The drug has also received approval and is commercially available in the European Union and the United Kingdom for treating adult RMS patients with active disease.
Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, expressed the company's satisfaction with the additional patents, emphasizing their importance in life cycle management and the potential to explore the drug's full capabilities in treating multiple sclerosis and other autoimmune diseases.
BRIUMVI® works by targeting a specific epitope on CD20-expressing B-cells, a method that has proven effective in managing autoimmune disorders. Its design omits certain sugar molecules, enhancing B-cell depletion efficiency at lower doses. However, the drug comes with contraindications for patients with active Hepatitis B Virus infection or a history of severe infusion reactions to BRIUMVI®. The most common adverse reactions reported in RMS trials were infusion reactions and upper respiratory tract infections.
TG Therapeutics is a biopharmaceutical company focused on acquiring, developing, and commercializing treatments for B-cell diseases. The company has a research pipeline with several investigational medicines and has successfully commercialized BRIUMVI® in the U.S. and Europe.
The newly issued patents are part of the company's strategy to protect and extend the commercial viability of BRIUMVI®. The information regarding these patents and the drug's approval is based on a press release statement from TG Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.